Therap Human Monoclonal Antibod for Treatment of Hantavirus Cardiopulmonary Syndr

项目5：用于治疗汉坦病毒心肺的治疗性人单克隆抗体 综合征(J. Botten，项目负责人）。 HCPS的治疗目前仅限于支持性护理。 利巴韦林虽然在体外有效地限制病毒复制，但尚未最终显示出对病毒复制的抑制作用。 有效缓解HCPS严重程度。给予来自回收HCPS的免疫血浆 已经证明，鹿鼠的病人可以保护啮齿动物免受病毒的攻击。这一目标将考验 通过产生一组人Fab被动施用中和抗体的功效 能够在体外中和的片段。该提案的长期目标是建立一家银行， 可用于治疗汉坦病毒的人单克隆抗体 感染.

Project 5: Therapeutic human monoclonal antibodies for treatment of hantavirus cardiopulmonary syndrome. (J. Botten, Project Leader). Treatment for HCPS is currently limited to supportive care. Ribavirin, while effective at restricting viral replication in vitro, has not conclusively been shown to be efficacious in alleviating HCPS severity. Administration of immune plasma from recovered HCPS patients to deer mice has been shown to protect rodents from viral challenge. This aim will test the efficacy of passive administration of neutralizing antibodies by generating a panel of human Fab fragments capable of in vitro neutralization. The long range goal of the proposal will be to develop a bank of human monoclonal antibodies which can be given therapeutically for the treatment of hantavirus infections.